Cancer Advisor

2026 Evidence Update | NED • Minimal Residual Disease • Cancer Recurrence • Metabolic Health • Survivorship • Repurposed Therapies Important: This article is an evidence-informed framework for discussing long-term cancer survivorship and recurrence-risk reduction with a qualified oncology team. It is not a universal cancer-maintenance protocol and should not be used to self-prescribe prescription medicines, veterinary drugs, supplements, fasting regimens, or other off-label therapies. Key Takeaway Achieving NED (No Evidence of Disease) is an important milestone, but it is not synonymous with a guarantee that cancer can never return. The modern survivorship question is therefore broader than simply: "Is there cancer on the scan?" A better question is: "How can we systematically reduce recurrence risk, detect molecular or clinical relapse as early as possible, preserve physical function, and maintain long-term metabolic and immune health?" This ...

Home  ›  Cancer Academy & Protocols Library  ›  Systems Oncology Series  ›  The New Blueprint for Cancer Treatment Narrative Review · Journal-Format Edition Systems Oncology Series · Part 3 A structured narrative evidence review, formatted for transparency of methods, sourcing, and evidence grading. Abstract Background: Checkpoint immunotherapy, CAR-T cell therapy, targeted therapy, antibody-drug conjugates, and now personalized mRNA cancer vaccines have each produced genuine, sometimes durable, benefit. Yet outcomes for advanced and metastatic disease remain limited chiefly by two intertwined biological properties that no single breakthrough has solved: tumor heterogeneity and phenotypic (lineage) plasticity . Objective: To synthesize current and emerging evidence on treatment-design strategies built specifically to counter heterogeneity and plasticity, and to organize them into a coherent framework for how cancer treatment is bei...